NanoString Takes Option to Liver Cancer Gene Signature for Possible Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – NanoString Technologies today announced it has secured the option to exclusively license a 186-gene signature from the Broad Institute that may be useful in determining the prognosis of patients diagnosed with hepatocellular carcinoma, or HCC.

In addition to potentially being useful for HCC, the gene signature may also help determine the prognosis of patients with hepatitis C-related early stage cirrhosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.

All the images that investigators produce through their research present a challenge to share, Nature News reports.

The House of Representatives science committee has approved a measure that includes new rules for large National Science Foundation projects, ScienceInsider reports.

In PLOS this week: founder mutation linked to some leukoencephalopathy cases, transcript and protein profiles of the kissing bug, and more.